BiondVax Receives Patent Approvals In Europe, Japan

October 29, 2014 | Israeli pharmaceutical company BiondVax, developing the universal flu vaccine, announced that it received approvals from the European Union and Japan’s patent authorities for the companies flu vaccines. The Multimeric Multi-Epitope Polypeptide Influenza Vaccines is a family of patents for vaccination against influenza in humans, vaccines that provide long-lasting protecting against a variety of flu strains. The approved patent in Europe and Japan was approved some time ago by authorities in the US, Hong Kong, Australia, China, Russia and Mexico. BiondVax is a publicly traded company that has created a universal flu vaccine to improve global protection against influenza.